Cognition Therapeutics (CGTX): Price and Financial Metrics

Cognition Therapeutics (CGTX): $0.47

0.00 (-0.25%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add CGTX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#199 of 329

in industry

CGTX Price/Volume Stats

Current price $0.47 52-week high $2.95
Prev. close $0.47 52-week low $0.34
Day low $0.47 Volume 238,700
Day high $0.48 Avg. volume 499,233
50-day MA $0.53 Dividend yield N/A
200-day MA $1.52 Market Cap 18.90M

CGTX Stock Price Chart Interactive Chart >


Cognition Therapeutics (CGTX) Company Bio


Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in phase 2 clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed phase 1 clinical trial to treat early-stage Alzheimer's disease; and in preclinical trial to treat dementia with Lewy bodies (DLB) and dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.


CGTX Latest News Stream


Event/Time News Detail
Loading, please wait...

CGTX Latest Social Stream


Loading social stream, please wait...

View Full CGTX Social Stream

CGTX Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
YTD N/A
2023 N/A
2022 N/A
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!